HSI1 23,753.84 0.00 --
HSCEI1 7,981.54 0.00 --
Back    Zoom +    Zoom - Block Traded
AKESO (09926.HK) Plunges as Much as 32% Amid Forced Selling as Ivonescimab Fails to Obtain FDA Approval for US Launch
2026-11-16 10:04:49
AKESO (09926.HK) shares once plunged 32% this morning (16th), hitting a low of HKD56.1. The stock was last reported at HKD60.6, down 26.37%, with trading volume surging to 28.1376 million shares, involving HKD1.724 billion in turnover.

AKESO's overseas partner Summit Therapeutics Inc. (SMMT.US) announced that it had received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the marketing application for self-developed PD-1/VEGF bispecific antibody ivonescimab. The application for the drug, in combination with chemotherapy, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) previously treated with EGFR-TKI therapy has not been approved at this stage.

The FDA stated that although the global Phase III HARMONi study supporting the application met its primary endpoint of progression-free survival, it failed to demonstrate a statistically significant improvement in overall survival.(mn/da)~

AASTOCKS Financial News
Website: www.aastocks.com

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.